https://doi.org/10.1140/epjs/s11734-025-01475-5
Review
Multi-faceted approach for identifying biomarkers for radiation injury and regulatory approval of radiation medical countermeasures
1
Department of Pharmacology and Molecular Therapeutics, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
2
Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
Received:
2
July
2024
Accepted:
20
January
2025
Published online:
3
February
2025
Acute radiation syndrome (ARS) is caused by high doses of ionizing radiation (> 2 Gy). ARS is broken down into 3 sub-syndromes: exposure to 2–6 Gy results in hematopoietic ARS (H-ARS), exposure to 6–10 Gy results in gastrointestinal ARS (GI-ARS), and exposure to greater than 10 Gy results in neurovascular ARS (NV-ARS). In case of nuclear warfare events such as the bombings of Hiroshima and Nagasaki, or nuclear meltdown scenarios, such as Chernobyl and Fukushima-Daiichi, it is essential to be prepared to treat and prevent the development of ARS. Therefore, the development of prophylactic (administered before radiation exposure) and therapeutic (administered post-irradiation) radiation medical countermeasures (MCMs) is paramount in this effort. Currently, there are only 9 approved MCMs and all 9 are therapeutics for H-ARS. Thus, it is integral to develop a prophylactic MCM that treats high doses of radiation exposure injury. Following the Food and Drug Administration’s (FDA) animal rule, we are researching biomarkers of ARS to analyze whether prospective MCMs are effective in mitigating ARS development in humans. In this article, we summarize the various state-of-the-art omics platforms (metabolomics/lipidomics, proteomics, microbiome, and transcriptomics) which have been used to identify candidate biomarkers for acute radiation injuries using murine and nonhuman primate models. We have reviewed outside literature in addition to studies carried out in our laboratory.
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
